Titre : | Mortality among individuals with cannabis, cocaine, amphetamine, MDMA, and opioid use disorders: A nationwide follow-up study of Danish substance users in treatment (2011) |
Auteurs : | M. ARENDT ; P. MUNK-JORGENSEN ; L. SHER ; S. O. W. JENSEN |
Type de document : | Article : Périodique |
Dans : | Drug and Alcohol Dependence (Vol.114, n°2-3, April 2011) |
Article en page(s) : | 134-139 |
Langues: | Anglais |
Discipline : | EPI (Epidémiologie / Epidemiology) |
Mots-clés : |
Thésaurus géographique DANEMARKThésaurus mots-clés MORTALITE ; CANNABIS ; COCAINE ; AMPHETAMINES ; MDMA-ECSTASY ; OPIOIDES ; INJECTION ; COMORBIDITE ; PSYCHOPATHOLOGIE ; COHORTE |
Résumé : | This is a register-based cohort study of 20,581 individuals in treatment for illicit substance use disorders in Denmark between 1996 and 2006. All in all, 1441 deaths were recorded during 111,445 person-years of follow-up. Standardized mortality ratios (SMRs) associated with different primary substance types were calculated and Cox-regression analyses were performed in order to establish hazard ratios (HR) associated with injection drug use and psychiatric comorbidity. SMRs for primary users of specific substances were: cannabis: 4.9 (95% confidence interval (CI): 4.2-5.8), cocaine: 6.4 (CI: 3.9-10.0), amphetamine: 6.0 (CI: 4.2-8.3), heroin: 9.1 (CI: 8.5-9.8), and other opioids 7.7 (CI: 6.6-8.9). For MDMA ('ecstasy') the crude mortality rate was 1.7/1000 person-years (CI: 0.4-7.0) and the SMR was not significantly elevated. Injection drug use was associated with significantly increased hazard ratios in users of opioids and cocaine/amphetamine. Overall, psychiatric comorbidity was not associated with increased mortality (HR: 1.1 [CI: 0.9-1.2], p = .28), but an association was found specifically among cocaine/amphetamine users (HR: 3.6 [CI: 2.1-6.4], p |
Domaine : | Drogues illicites / Illicit drugs |
Affiliation : | Unit for Psychiatric Research, Aalborg Psychiatric Hospital, Aarhus University Hospital, Molleparkvej 10, 9100 Aalborg, Denmark / Danemark |
Accueil